DQ1001 for Hard-to-Treat Multiple Myeloma
Part of Cancer clinical trials.
This early-stage trial tests a new drug called DQ1001 for multiple myeloma that has stopped responding to prior treatments. The drug is designed to target specific markers on myeloma cells and may help patients whose cancer has come back or become resistant to previous therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsed or refractory multiple myeloma (cancer that returned or stopped responding to treatment) and have received at least three prior treatment regimens
- Your cancer shows disease progression during or within two months after your most recent therapy
- Your myeloma cells test positive for BCMA or GPRC5D markers (detected through bone marrow/blood test or tissue biopsy)
- You have measurable disease at screening, such as detectable protein levels in blood or urine
- You are between 18 and 70 years old and in good enough health to tolerate the study (ECOG performance status 0–2)
- You have adequate organ function: reasonable blood cell counts, liver and kidney function, heart function (ejection fraction ≥50%), and oxygen levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This early-stage trial tests a new drug called QI-019B in patients whose multiple myeloma (a blood cancer) has stopped responding to standard treatments. The study checks if QI-019B is safe and whether it helps slow or stop the cancer's growth.
This trial tests whether giving a bispecific antibody (GPRC5D/CD3) before BCMA CAR-T cell therapy can help people with multiple myeloma that has come back or is not responding to treatment. It aims to improve outcomes for patients who have already tried many other treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Hear when a new Multiple Myeloma Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.